Biofrontera Inc. (BFRI)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
$1.55
+6.16%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$23.0M
Shares Outstanding
14.9M
P/S (TTM)
0.5x
Exchange
NCM
Currency
USD
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 7.0M | 17.1M | 10.1M | 12.0M |
| Gross Profit | 4.9M | 14.1M | 8.0M | 9.6M |
| Operating Income | (6.3M) | 4.6M | (3.9M) | (524K) |
| Net Income | (6.6M) | 5.6M | (4.8M) | (604K) |
| Diluted EPS | $-0.62 | $0.48 | $-0.41 | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 28.7M | 34.1M | 37.3M | 41.7M |
| Gross Profit | 13.5M | 16.6M | 18.7M | 30.7M |
| Operating Income | (22.4M) | (22.6M) | (17.2M) | (11.3M) |
| Net Income | (640K) | (20.1M) | (17.8M) | (10.5M) |
| Diluted EPS | $-0.48 | $-13.02 | $-3.22 | $-0.90 |